tion and high consensus expectations. • HIV: Gilead has done a good job of switching naïve patients to the new STRs (Stribild and Complera), but TruvadaiAtripla still hold -60% of the market right now. which means a significant number still need to be switched. This is a potential source of LT risk. Howev